Livzon Pharmaceutical Signs 2025 Agreements with Joincare

Livzon Pharmaceutical Group (HK:1513) has released an update.

Livzon Pharmaceutical Group has announced a series of framework agreements with its controlling shareholder, Joincare, for the year 2025. These agreements involve transactions related to water, electricity, labor services, and product sales and purchases, with a combined annual cap exceeding RMB 500 million. The deals, which fall under Hong Kong’s connected transactions regulations, highlight Livzon’s ongoing business synergy with Joincare.

For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.